Poly-L-lysine-coated nanoparticles are ineffective in inducing mucosal immunity against group a streptococcus

Abstract Background: Group A Streptococcus (GAS) can cause a range of maladies, from simple throat infections to lethal complication, such as rheumatic heart disease. The M-protein, a bacterial cell surface protein, is

[1]  Ashwini Kumar Giddam,et al.  Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus. , 2017, Current drug delivery.

[2]  W. M. Hussein,et al.  Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus. , 2016, International journal of pharmaceutics.

[3]  W. M. Hussein,et al.  Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery. , 2016, Nanomedicine.

[4]  M. Skwarczynski,et al.  Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus. , 2016, Acta biomaterialia.

[5]  W. M. Hussein,et al.  Structure-activity relationship of lipid core peptide-based Group A Streptococcus vaccine candidates. , 2016, Bioorganic & medicinal chemistry.

[6]  M. Skwarczynski,et al.  Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus. , 2016, Nanomedicine.

[7]  M. Skwarczynski,et al.  Peptide-based synthetic vaccines , 2015, Chemical science.

[8]  H. Kiyono,et al.  Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice , 2015, PloS one.

[9]  F. Qian,et al.  Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies , 2015, Protein & Cell.

[10]  Istvan Toth,et al.  Recent advances in peptide-based subunit nanovaccines. , 2014, Nanomedicine.

[11]  M. Skwarczynski,et al.  Oral delivery of nanoparticle-based vaccines , 2014, Expert review of vaccines.

[12]  I. Toth,et al.  Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes. , 2012, Journal of medicinal chemistry.

[13]  N. Lycke.  Recent progress in mucosal vaccine development: potential and limitations , 2012, Nature Reviews Immunology.

[14]  K. Yuen,et al.  Streptococcus pyogenes and re-emergence of scarlet fever as a public health problem , 2012, Emerging Microbes & Infections.

[15]  I. Toth,et al.  Immunological Evaluation of Lipopeptide Group A Streptococcus (GAS) Vaccine: Structure-Activity Relationship , 2012, PloS one.

[16]  M. Skwarczynski,et al.  Peptide-based subunit nanovaccines. , 2011, Current drug delivery.

[17]  M. Trucco,et al.  A Microsphere-Based Vaccine Prevents and Reverses New-Onset Autoimmune Diabetes , 2008, Diabetes.

[18]  I. Toth,et al.  Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. , 2008, Journal of medicinal chemistry.

[19]  S. Kaveri,et al.  A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes , 2007, Proceedings of the National Academy of Sciences.

[20]  V. Apostolopoulos,et al.  Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. , 2007, Vaccine.

[21]  G. Orefici,et al.  Therapeutic Failures of Antibiotics Used To Treat Macrolide-Susceptible Streptococcus pyogenes Infections May Be Due to Biofilm Formation , 2006, Journal of Clinical Microbiology.

[22]  D. Doolan,et al.  Synthesis and immunological evaluation of peptide-based vaccine candidates against malaria , 2016 .

[23]  M. Skwarczynski,et al.  Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery. , 2011, Methods in molecular biology.